<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140187</url>
  </required_header>
  <id_info>
    <org_study_id>S2021-344-01</org_study_id>
    <nct_id>NCT05140187</nct_id>
  </id_info>
  <brief_title>CMV-TCR-T Cells for CMV Infection After Allogenic HSCT</brief_title>
  <official_title>Adoptive Immunotherapy With Donor-derived CMV-TCR-T Cells for Patients With CMV Infection After Allogenic HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single arm, open-label, phase I study to determine the safety and&#xD;
      effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after allogenic&#xD;
      HSCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation&#xD;
      (HSCT) is common and can be lethal without prompt treatment. In this prospective study,&#xD;
      HLA-A*02:01/11:01/24:02-restricted CMV-specific T cell receptor (TCR) will be introduced into&#xD;
      donor T cells by ex vivo lentiviral transduction to generate CMV-TCR-T cells. An escalated&#xD;
      dose ranging from 1×10^4 to 1×10^7 of CMV-TCR-T cells will be infused into patients with CMV&#xD;
      infection. The safety, efficacy, pharmacokinetics and cytokine levels of allogenic CMV-TCR-T&#xD;
      cell therapy will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of CMV-DNA copies number</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative PCR will be used to determine viral copy numbers in peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CMV-TCR-T cells</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative PCR using primers specific for the gene encoding CMV-TCR will be used to determine the number of circulating CMV-TCR-T cells in peripheral blood post infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>CMV Infection After Allogenic HSCT</condition>
  <arm_group>
    <arm_group_label>CMV-TCR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with CMV infection after HSCT will receive a single infusion of donor-derived CMV-TCR-T cells, with the escalated dose ranging from 1×10^4 to 1×10^7 CMV-TCR-T cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV-TCR-T cells</intervention_name>
    <description>The patients with CMV infection after HSCT will receive a single infusion of donor-derived CMV-TCR-T cells, with the escalated doses including 1×10^4, 1×10^5, 1×10^6 and 1×10^7 CMV-TCR-T cells.</description>
    <arm_group_label>CMV-TCR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Age 1-60 years, gender unlimited. 2. Diagnosed with hematologic malignancies and have&#xD;
        undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), with CMV&#xD;
        infection after allo-HSCT.&#xD;
&#xD;
        3. Karnofsky Score ≥ 70 or Lansky Score ≥ 50. 4. TCR-T cell donor inclusion criteria:&#xD;
&#xD;
          1. Age ≥ 8 years.&#xD;
&#xD;
          2. Understand and voluntarily sign informed consent and are willing to comply with&#xD;
             laboratory tests and other research procedures.&#xD;
&#xD;
          3. ≥ 3/6 HLA match with TCR-T cell recipients enrolled.&#xD;
&#xD;
          4. Lymphocyte count = (0.8~4) × 10^9/L&#xD;
&#xD;
          5. Have sufficient venous circulation, without any symptoms that do not allow blood cell&#xD;
             isolation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with active aGVHD one day before TCR-T cell infusion.&#xD;
&#xD;
          2. Patients with severe kidney disease (Cr &gt; 3×normal value), liver damage (TBIL&#xD;
             &gt;2.5×upper limit of normal value, ALT and AST &gt; 3×upper limit of normal value) or&#xD;
             heart failure (NYHA heart function grade IV) one week before TCR-T cell infusion.&#xD;
&#xD;
          3. Anticipated to take immunosuppressive hormones on the day of TCR-T cell infusion.&#xD;
&#xD;
          4. Have other malignancies.&#xD;
&#xD;
          5. Have relapsed and uncontrolled hematologic malignancies.&#xD;
&#xD;
          6. Serologically positive for HIV-Ab or TAP-ab.&#xD;
&#xD;
          7. Positive for EBV DNA.&#xD;
&#xD;
          8. Anticipated to have other cell therapies in 4 week post TCR-T cell infusion.&#xD;
&#xD;
          9. Pregnant or lactating women。&#xD;
&#xD;
         10. Participated in any other clinical study of drugs and medical devices before 30 days&#xD;
             of enrollment.&#xD;
&#xD;
         11. Any condition that would, in the investigator's judgment, interfere with full&#xD;
             participation in the study, including administration of study drug and attending&#xD;
             required study visits; pose a significant risk to the subject; or interfere with&#xD;
             interpretation of study data.&#xD;
&#xD;
         12. TCR-T cell donor exclusion criteria:&#xD;
&#xD;
        1) Positive for any of the following: HbsAg, HBeAg, HBV-DNA, HCV-Ab, HCV-RNA, HIV-Ab,&#xD;
        TP-Ab, EBV-DNA or CMV-DNA.&#xD;
&#xD;
        2) Other uncontrolled infection. 3) Have taken immunosuppressive drugs 1 week before PBMC&#xD;
        collection. 4) Any condition that would, in the investigator's judgment, make it unsuitable&#xD;
        for the donors to be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daihong Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daihong Liu</last_name>
    <phone>86-13681171597</phone>
    <email>daihongrm@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liping Dou</last_name>
    <phone>86-13681207138</phone>
    <email>lipingruirui@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daihong Liu, doctor</last_name>
      <phone>86-13681171597</phone>
      <email>daihongrm@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Liping Dou, doctor</last_name>
      <phone>+8613681207138</phone>
      <email>lipingruirui@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Daihong Liu</investigator_full_name>
    <investigator_title>Directer</investigator_title>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

